Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003185 · ClinicalTrials.gov registry record · Phase 2

Biological Therapy in Treating Patients With Glioblastoma Multiforme

A Phase 2 study, sponsored by The Cleveland Clinic.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00003185: Completed Phase 2 study, sponsored by The Cleveland Clinic.

NCT00003185 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003185, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.

Interventions

  • DRUG cyclophosphamide
  • PROCEDURE conventional surgery
  • BIOLOGICAL sargramostim
  • BIOLOGICAL autologous tumor cell vaccine
  • BIOLOGICAL tumor-draining lymph node lymphocyte therapy

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 1997-08
Est. Completion 1998-07
Phase Phase 2
The Cleveland Clinic

688 total trials

What the finished NCT00003185 record still lists

NCT00003185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00003185 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003185 about?

NCT00003185 is a clinical study titled "Biological Therapy in Treating Patients With Glioblastoma Multiforme". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.

What is the current status of trial NCT00003185?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1997-08. Estimated completion is 1998-07.

What interventions are being tested in trial NCT00003185?

The interventions under investigation include: cyclophosphamide (DRUG), conventional surgery (PROCEDURE), sargramostim (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), tumor-draining lymph node lymphocyte therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT00003185?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003185's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003185, the US trial registry maintained by the National Library of Medicine. NCT00003185 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.